(Q33447738)

26 July 2017

Riociguat (BAY 63-2521) and warfarin: a pharmacodynamic and pharmacokinetic interaction study. (English)

1 reference

26 July 2017

1 reference

ChEBI release 2020-05-28

1 reference

1 reference

1 reference

Reiner Frey

1

1 reference

26 July 2017

Wolfgang Mück

2

1 reference

26 July 2017

Nina Kirschbaum

3

1 reference

26 July 2017

Jörn Krätzschmar

4

1 reference

26 July 2017

Gerrit Weimann

5

1 reference

26 July 2017

Georg Wensing

6

1 reference

26 July 2017

27 August 2010

1 reference

The Journal of Clinical Pharmacology

26 July 2017

1 reference

26 July 2017

51

1 reference

26 July 2017

7

1 reference

26 July 2017

1051-1060

1 reference

Survival in patients with primary pulmonary hypertension. Results from a national prospective registry.

26 July 2017

1 reference

https://api.crossref.org/works/10.1177%2F0091270010378119

NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010378119

Pulmonary Arterial Hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010378119

Nitric oxide activates guanylate cyclase and increases guanosine 3′:5′-cyclic monophosphate levels in various tissue preparations

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010378119

Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010378119

Single-dose pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase stimulator BAY 63-2521: an ascending-dose study in healthy male volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010378119

First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010378119

Thrombotic arteriopathy and anticoagulation in pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010378119

Do patients with primary pulmonary hypertension develop extensive central thrombi?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010378119

Treatment of pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010378119

ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American Coll

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010378119

Evaluation and management of the patient with pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010378119

Updated evidence-based treatment algorithm in pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010378119

Systematic overview of warfarin and its drug and food interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010378119

Human P450 metabolism of warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010378119

Clinical consequences of cytochrome P450 2C9 polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010378119

Pharmacogenetics of warfarin elimination and its clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010378119

Genetic polymorphisms of human N-acetyltransferase, cytochrome P450, glutathione-S-transferase, and epoxide hydrolase enzymes: relevance to xenobiotic metabolism and toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010378119

Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010378119

Warfarin and the vitamin K-dependent gamma-carboxylation system

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010378119

Identification of the gene for vitamin K epoxide reductase

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010378119

Pharmacogenetics of warfarin: current status and future challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010378119

A regulatory science perspective on warfarin therapy: a pharmacogenetic opportunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010378119

Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010378119

Sitaxsentan: a selective endothelin-A receptor antagonist, for the treatment of pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010378119

Sildenafil: a review of its use in pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010378119

Significant pharmacokinetic and pharmacodynamic interaction of warfarin with the NO-independent sGC activator HMR1766.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010378119

NO-independent, haem-dependent soluble guanylate cyclase stimulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010378119

Antiplatelet properties of a novel, non-NO-based soluble guanylate cyclase activator, BAY 41-2272.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010378119

The largest prospective warfarin-treated cohort supports genetic forecasting

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010378119

21 January 2018

Identifiers

DOI

10.1177/0091270010378119

1 reference

26 July 2017

1 reference